Oncogenex Pharmaceuticals, Inc.
Formerly Sonus Pharmaceuticals Inc.
Oncogenex Pharmaceuticals, Inc. is listed today as Achieve Life Sciences, Inc.: market value, financials and filings are on its company page.
Funding rounds
1 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Dec 2009 | $10 M | No. 1 | $10 to $50 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Oncogenex Pharmaceuticals, Inc. had no revenue when it filed its newest notice of a funding round (Jan 2010).
SEC Form D (revenue range) · Jan 2010
The industry group it chose in its notices: Pharmaceuticals.
SEC Form D · Jan 2010
Products and services#
No products or services of Oncogenex Pharmaceuticals, Inc. are on record.
Investors#
No investor of Oncogenex Pharmaceuticals, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 1 investors.
Largest shareholders today
Institutions holding Achieve Life Sciences, Inc. shares, as of Sep 30, 2026.
- Frazier Life Sciences Management, L.P.$62 M6.92%
- TPG GP A, LLC$56 M6.25%
- venBio Partners LLC$48 M5.38%
- Venrock Adviser, LLC$45 M5.00%
- BlackRock, Inc.$44 M4.99%
- Paradigm Biocapital Advisors LP$40 M4.50%
- Propel Bio Management, LLC$31 M3.51%
- Jpmorgan Chase & Co$31 M3.44%
- Marshall Wace, LLP$31 M3.43%
- State Street Corp$30 M3.38%
- Eventide Asset Management, LLC$29 M3.25%
- Vanguard Capital Management LLC$28 M3.16%
- Logos Global Management LP$26 M2.91%
- Franklin Templeton Inc$25 M2.85%
- Janus Henderson Group Ltd.$22 M2.50%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Cindy A. Jacobs | Executive officer | Jan 2010 |
| Scott Cormack | Executive officer | Jan 2010 |
| Stephen A. Anderson | Executive officer | Jan 2010 |
| Dwight A. Winstead | Director | Jan 2010 |
| Michael A. Martino | Director | Jan 2010 |
| Michelle A. Burris | Director | Jan 2010 |
| Neil James Clendeninn | Director | Jan 2010 |
| Scott Cormack | Director | Jan 2010 |
Went public since 2011. Its SEC number is that of a company listed on a stock exchange.